Artificial intelligence (AI) has seen rapid growth, transforming industries and daily life. From chatbots to advanced ...

However, the placebo group also saw a 1.98-point in ... Along with LSR, Vertex is also running a trial of suzetrigine in painful diabetic peripheral neuropathy (DPN), another form of chronic ...

Artificial intelligence (AI) has seen rapid growth, transforming industries and daily life. From chatbots to advanced ...

Other unsolved mathematical mysteries are akin to the branches of trees. The trees themselves—fields within the wider subject of math —are strong and towering, rooted firmly in established findings.

Can generative AI (gen AI) rip things apart and then try to glue it all back together with more insight, more intelligence, more efficiency, and more value? It really depends on what the application ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.